Kyverna appoints Mayo Pujols as CTO; Karen Walker retires effective Feb 9, 2026

Kyverna Therapeutics, Inc.

Mayo Pujols named CTO effective Feb 9, bringing 30+ years in CAR T and cell therapy manufacturing.
Outgoing CTO Karen Walker retires; will consult on BLA submission for miv-cel in stiff person syndrome.
Pujols receives an inducement option for 300,000 shares vesting over 4 years under the 2024 Inducement Plan.
The inducement plan was amended to increase authorized shares by 1,000,000 to 5,000,000 total.
Kyverna advances toward potential commercial launch of miv-cel for autoimmune diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.